New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., entered into a licensing agreement with Evive Biotech a subsidiary of China's Yifan Pharmaceutical Company Ltd., to commercialize Ryzneuta in the U.S. market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is presently under late-stage...
India's Aurobindo to Acquire Drug Under Development from Advent Pharma
Hyderabad, India-based Aurobindo Pharma's U.S. subsidiary Aurobindo Pharma USA Inc signed a pact to acquire an under-development product and certain related assets from Australia's Advent Pharmaceuticals Pty Ltd., for $12.5 million. The time period for completion of the deal is January 2019. Advent is a specialty pharmaceutical R&D company based in Melbourne,...